Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ainuovirine pharmacokinetics with rifampicin- or rifabutin-based tuberculosis therapy in adults with HIV-1 and tuberculosis coinfection
ChiCTR2400082932Phase 4Not yet recruiting
- Sponsor
- Guiyang Public Health Clinical Center
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ainuovirine in Human immunodeficiency virus infection type 1 and Tuberculosis (TB) (3 arms), sponsored by Guiyang Public Health Clinical Center. Primary endpoint: Pharmacokinetic parameters. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
ainuovirine
03
Conditions
Human immunodeficiency virus infection type 1Tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR2400082932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082932.